Product Information
RIZATRIPTAN 5 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.3480 per EA under NDC 57237008763. Its NADAC has been published 478 times since Aug 9, 2017.
FDA first approved this application on Dec 31, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
57237008763
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIZATRIPTAN BENZOATEApproval Type
Generic (ANDA)
FDA Application
ANDA202490FDA Approved
12/31/2012
TE Code
AB
On Market Since
12/31/2012
Pharmacological Classes
Price Statistics
The NADAC for RIZATRIPTAN 5 MG TABLET has been published 478 times since Aug 9, 2017, and over the history we have for it it has declined 67.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3480 per EA |
|---|---|
| All-time high | $1.0560 (Aug 16, 2017) |
| All-time low | $0.3203 (Jul 17, 2024) |
| 52-week high | $0.5666 |
| 52-week low | $0.3446 |
| Median price | $0.6169 |
| Average price | $0.6541 |
| Largest weekly change | +74.4% (Aug 21, 2024) |
| Weeks tracked | 478 |
| Tracking since | Aug 9, 2017 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rizatriptan Benzoate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIZATRIPTAN 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RIZATRIPTAN 5 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.3480 per EA (NDC 57237008763), effective Sep 30, 2026.
How has the price of RIZATRIPTAN 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for RIZATRIPTAN 5 MG TABLET has declined 67.0%. It has been tracked across 478 weekly CMS publications since Aug 9, 2017.
What are the highest and lowest recorded NADAC prices for RIZATRIPTAN 5 MG TABLET?
Since Aug 9, 2017, the NADAC for RIZATRIPTAN 5 MG TABLET has ranged from a low of $0.3203 (Jul 17, 2024) to a high of $1.0560 (Aug 16, 2017), with a median of $0.6169 per EA.
Are there cheaper alternatives to RIZATRIPTAN 5 MG TABLET?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RIZATRIPTAN 5 MG TABLET, is $0.3203 per EA — about 8% below RIZATRIPTAN 5 MG TABLET.
Who manufactures RIZATRIPTAN 5 MG TABLET?
RIZATRIPTAN 5 MG TABLET (NDC 57237008763) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.